New drug combo for advanced bile duct cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of drugs for people with advanced bile duct or gallbladder cancer that has not been treated yet. It aims to see if the combination can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have advanced or spread bile duct or gallbladder cancer, confirmed by a biopsy.
- You have not had any previous chemotherapy or other cancer treatment for this cancer.
- You are able to do your daily activities (performance status 0 or 1).
- Your blood counts and liver/kidney function are good enough, based on blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug combined with standard chemotherapy as a first treatment for advanced bile duct or gallbladder cancer. It may help your immune system fight the cancer while chemotherapy attacks the tumor directly.
This study tests a combination of freezing the tumor (cryoablation), an investigational immunotherapy (QL1706), and a targeted therapy pill (lenvatinib) for people with advanced bile duct cancer that has progressed after initial treatment. The goal is to see if this new combination can help control the cancer and improve outcomes.
This trial tests a combination of two drugs, sacituzumab tirumotecan and pembrolizumab, for people with advanced bile duct or gallbladder cancer that has grown after previous treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This study tests a combination of four drugs—two immunotherapy drugs (iparomlimab and toripalimab), a targeted therapy (bevacizumab), and chemotherapy—as a first-line treatment for advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new drug called mitazalimab, which helps the immune system fight cancer, combined with standard chemotherapy (FOLFOX) for people whose bile duct or gallbladder cancer did not respond to or stopped responding to initial immunotherapy. The goal is to see if this combination can shrink tumors or slow cancer growth better than chemotherapy alone.
This trial tests a combination of three drugs for bile duct cancer that cannot be removed by surgery: sintilimab (an immunotherapy that helps your immune system fight cancer), bevacizumab (a drug that blocks blood vessel growth to tumors), and a standard chemotherapy called AG (gemcitabine and capecitabine). The goal is to see if this combination can help shrink or control the cancer as a first treatment option.
Hear when a new Biliary Tract Cancer (BTC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.